Stimulation of breast cancer cellsin vitro by the environmental estrogen enterolactone and the phytoestrogen equol
- 162 Downloads
The phenolic lignans enterolactone and enterodiol appear periodically in women's urine, dependent upon synthesis from plant-derived lignans by the intestinal microflora. The phytoestrogen equol is also present in women's urine, and is also derived from a vegetarian diet. Antiestrogenic or antiproliferative actions of these compounds have been postulated and related to the observation that there is a reduced incidence of breast cancer associated with diet. We evaluated the estrogenic and antiestrogenic activity of these compounds using four sensitive assays in tissue culture, including the use of human breast cancer cell lines T47D and MCF-7. Unexpectedly, we found that enterolactone and enterodiol, as well as equol, are weak estrogens, and that enterolactone and equol could stimulate the growth of estrogen-dependent breast cancer cell lines. We suggest that these environmental agents can promote the growth of breast cancer, particularly hormone-dependent metastases that may be located near the gut or in the mesenteries or liver, where the concentration of these intestinally produced compounds would be highest. Treatment with an antiestrogen such as tamoxifen blocks the estrogenic activity of these compounds. In the absence of treatment with an antiestrogen such as tamoxifen, hormonal therapy to block steroidal estrogen synthesis in a patient with breast cancer could conceivably be circumvented by a vegeterian diet rich in the precursors to estrogenic compounds such as enterolactone and equol.
Key wordsdietary estrogens enterodiol enterolactone equol estrogen-stimulated growth hormone-dependent breast cancer phytoestrogens
Unable to display preview. Download preview PDF.
- 8.Dehennin L, Reiffsteck A, Jondet M, Thibier M: Identification and quantitative estimation of a lignan in human and bovine semen. J Reprod Fert 66: 305–309, 1982Google Scholar
- 9.Cooley G, Farrant RD, Kirk DN, Patel S, Wynn S, Buckingham MJ, Hawakes GE, Hursthouse MB, Galas AMR, Lawson AM, Setchell KDR: Structural analysis of the urinary lignan 2,3-bis-(3-hydroxybenzyl)butan-4-olide (‘enterolactone’). A 400 MHz nuclear magnetic resonance study for the solution state and x-ray study for the crystal state. J Chem Soc Perkin Trans 2: 489–497, 1984Google Scholar
- 10.Borriello SP, Setchell KDR, Axelson M, Lawson AM: Production and metabolism of lignans by the human faecal flora. J App Bact 58: 37–43, 1985Google Scholar
- 11.Walters AP, Knowler JT: Effect of a lignan (HPMF) on RNA synthesis in the rat uterus. J Reprod Fert 66: 379–381, 1982Google Scholar
- 20.Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME: Structure-activity relationships of estrogens. Envir Health Perspec 61: 97–110, 1985Google Scholar
- 24.Lippman ME, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976Google Scholar
- 28.Setchell KDR, Borriello SP, Hulme P, Kirk DN, Axelson M: Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutrition 40: 569–578, 1984Google Scholar
- 32.Holst J, Cajander S, Carlström K, Damber M-G, von Schoultz B: A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Brit J Obstet Gynaecol 90: 355–360, 1983Google Scholar